Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dabigatran in TIA and Minor Stroke
NCT02295826Phase 2Completed
- Sponsor
- University of Alberta
- Start
- Jan 2015
- Primary completion
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of dabigatran in Transient Ischemic Attack (TIA) and ischemic stroke (2 arms), sponsored by University of Alberta. Primary endpoint: Rate of symptomatic hemorrhagic transformation at 5 weeks. Started Jan 2015; status: completed.
02
Drugs
dabigatran
03
Conditions
Transient Ischemic Attack (TIA)ischemic stroke
Beyond the preview
Go deeper on NCT02295826.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02295826.